Metabolite Identification Studies
The FDA guidance for Safety Testing of Drug Metabolites recommends that the structure of any metabolite which may represent more than 10 % of the exposure in humans should be formally elucidated. The earlier a disproportionate metabolite is recognized and characterised in the drug development process, the lower the risk of downstream delays with better planning of clinical studies.
The expertise and experience, in conjunction with state-of-the-art technology, are available within Arcinova to advise on the optimal approaches for completion of metabolite isolation and identification. Where possible, isolation can be circumvented by hyphenated technologies. The in-house mass spectrometry – Nuclear Magnetic Resonance platform not only enables identification of metabolites, but it permits quantification within a biological matrix.
CPhI WorldwideCPhI Worldwide will be attended by Nathalie Huther, Business Development Manager Europe. Nathalie will be located at the DIT stand: 9J40
CPhI WorldwideDates: 9th - 11th OctoberLocation: Madrid, Spain
CMAC Open DayThe CMAC Open Day event will be attended by Gareth Jenkins, Chief Scientific Officer.
CMAC Open DayDates: 25th - 26th OctoberLocation: Glasgow, UK
Organic Process Research & DevelopmentThe Organic Process R&D conference will be attended by Nathalie Huther, Business Development Manager Europe.
Organic Process Research & DevelopmentDates: 29th - 31st OctoberLocation: Milan, Italy